Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05787470 · ClinicalTrials.gov registry record

State of Hormones Impact Nociceptive Expression

A clinical trial of Pain and Gender Identity, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
120
Enrollment target
1
Study location

NCT05787470: Recruiting study of Pain and Gender Identity, sponsored by University of Alabama at Birmingham.

NCT05787470 is a study of Pain and Gender Identity that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 120 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05787470, a study of Pain and Gender Identity, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
120 participants
Enrollment target
1
Study location

Study Summary

The Investigators have recently published on differences in pain sensitivity measures between cis and trans individuals in the local area. The investigators observed the anticipated differences in pain sensitivity between CM and CW (CW \> CM), but found that the TW were phenotypically similar to CW in all measures. However, the investigators did not assess hormone level, nor did the investigators recruit TM participants. Here, with the assistance of two local community group stakeholders the investigators will recruit the following groups: CM, CW, TM+T (currently taking exogenous testosterone), TW+E (exogenous estradiol), TM, and TW (n=20/group). The investigators will use quantitative sensory testing to assess sensitivity to cold, pressure, and heat via standardized protocols. Blood samples will be taken for assessment of stress and reproductive hormone levels, immune cell populations and stimulated cytokine release. Finally, questionnaires will measure pain state, quality of life (QOL), voice QOL, body image, appearance, self-reported health, masculinity/femininity, community connectedness, gender role, sleep, depression, social support, adverse childhood experiences and stigma.

Primary Outcome

Heat pain thresholds will be taken with a slowing increasing temperature probe. The temperature at which pain is first detected over repeated tests will be the heat pain threshold.

Conditions Studied

Pain Gender Identity

Interventions

  • DIAGNOSTIC_TEST Blood Draw
  • BEHAVIORAL Quantative sensory testing

Study Locations (1)

Alabama

  • University of Alabama at Birmingham - Birmingham

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2023-03-01
Est. Completion 2026-07-31
University of Alabama at Birmingham

1,160 total trials

What NCT05787470 shows while recruiting

NCT05787470 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 304-participant average among 374 other Pain trials with a reported enrollment target (61% lower).

The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Blood Draw is the first listed.

NCT05787470 reports a single indexed study location in Alabama.

Frequently Asked Questions

What is clinical trial NCT05787470 about?

NCT05787470 is a clinical study titled "State of Hormones Impact Nociceptive Expression". The Investigators have recently published on differences in pain sensitivity measures between cis and trans individuals in the local area. The investigators observed the anticipated differences in pain sensitivity between CM and CW (CW \> CM), but found that the TW were phenotypically similar to CW ...

What is the current status of trial NCT05787470?

This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2023-03-01. Estimated completion is 2026-07-31.

What conditions does trial NCT05787470 study?

This clinical trial studies the following conditions: Pain, Gender Identity.

What interventions are being tested in trial NCT05787470?

The interventions under investigation include: Blood Draw (DIAGNOSTIC_TEST), Quantative sensory testing (BEHAVIORAL).

Who is sponsoring clinical trial NCT05787470?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05787470 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05787470's enrollment target sits among peer trials

120 135th of 374 higher than 229 of 374 other Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05787470

Source: ClinicalTrials.gov NCT05787470, the US trial registry maintained by the National Library of Medicine. NCT05787470 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.